| Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy … KR Chapman, JR Hurst, SM Frent, M Larbig, R Fogel, T Guerin, D Banerji, ... American journal of respiratory and critical care medicine 198 (3), 329-339, 2018 | 236 | 2018 |
| Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study W Vincken, J Aumann, H Chen, M Henley, D McBryan, P Goyal International journal of chronic obstructive pulmonary disease, 215-228, 2014 | 94 | 2014 |
| Optimizing identification and management of COPD patients–reviewing the role of the community pharmacist T van der Molen, JFM van Boven, T Maguire, P Goyal, P Altman British Journal of Clinical Pharmacology 83 (1), 192-201, 2017 | 72 | 2017 |
| Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross … P Altman, L Wehbe, J Dederichs, T Guerin, B Ament, MC Moronta, ... BMC pulmonary medicine 18, 1-8, 2018 | 60 | 2018 |
| Comparative efficacy of long-acting â2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis JF Donohue, KA Betts, EX Du, P Altman, P Goyal, DL Keininger, ... International journal of chronic obstructive pulmonary disease, 367-381, 2017 | 45 | 2017 |
| Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies A D¢Urzo, E Kerwin, T Overend, P D¢Andrea, H Chen, P Goyal Current medical research and opinion 30 (3), 493-508, 2014 | 42 | 2014 |
| Long-term triple therapy de-escalation to indacaterol/glycopyrronium in COPD patients (SUNSET): a randomized, double-blind, triple-dummy clinical trial KR Chapman, JR Hurst, SM Frent, M Larbig, R Fogel, T Guerin, D Banerji, ... American Journal of Respiratory and Critical Care Medicine 198 (3), 329-339, 2018 | 32 | 2018 |
| Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data AD D¢Urzo, EM Kerwin, KR Chapman, M Decramer, R DiGiovanni, ... International Journal of Chronic Obstructive Pulmonary Disease, 1599-1612, 2015 | 26 | 2015 |
| Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study JA Wedzicha, D Singh, I Tsiligianni, C Jenkins, S Fucile, R Fogel, S Shen, ... Respiratory research 20, 1-8, 2019 | 18 | 2019 |
| Predicting hospitalization due to COPD exacerbations in Swedish primary care patients using machine learning–based on the ARCTIC study B Ställberg, K Lisspers, K Larsson, C Janson, M Müller, M Łuczko, ... International journal of chronic obstructive pulmonary disease, 677-688, 2021 | 15 | 2021 |
| Cost-effectiveness of glycopyrronium bromide compared with tiotropium in patients with chronic obstructive pulmonary disease in Sweden M Costa-Scharplatz, B Ställberg, P Goyal, Y Asukai, JB Gruenberger, ... Applied health economics and health policy 13, 637-645, 2015 | 15 | 2015 |
| Developing a short-term prediction model for asthma exacerbations from Swedish primary care patients¢ data using machine learning-Based on the ARCTIC study K Lisspers, B Ställberg, K Larsson, C Janson, M Müller, M Łuczko, ... Respiratory Medicine 185, 106483, 2021 | 12 | 2021 |
| Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials A D¢Urzo, G Bader, S Shen, P Goyal, P Altman NPJ Primary Care Respiratory Medicine 28 (1), 18, 2018 | 8 | 2018 |
| All-serotype dengue virus detection through multilayered origami-based paper/polymer microfluidics P Biswas, GN Mukunthan Sulochana, TN Banuprasad, P Goyal, D Modak, ... ACS sensors 7 (12), 3720-3729, 2022 | 7 | 2022 |
| Multifunctional Fe3O4-ZnO nanocomposites for environmental remediation applications. Environ Nanotechnol Monit Manag 10: 28–35 P Goyal, S Chakraborty, SK Misra | 7 | 2018 |
| Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials DMG Halpin, CF Vogelmeier, K Mezzi, P Gupta, K Kostikas, JA Wedzicha ERJ Open Research 7 (1), 2021 | 3 | 2021 |
| Use of Machine learning to predict asthma exacerbations C Janson, G Johansson, K Larsson, B Ställberg, M Mueller, M Luczko, ... European Respiratory Journal 56 (suppl 64), 2020 | 3 | 2020 |
| Withdrawal of inhaled corticosteroids from COPD patients inhaling long-term triple therapy: the SUNSET Study KR Chapman, J Hurst, SM Frent, M Larbig, R Fogel, T Guerin, D Banerji, ... A15. ICS in Copd: The Pendulum Keeps Swinging, A1009-A1009, 2018 | 3 | 2018 |
| Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD … W Vincken, J Aumann, P Goyal, P Altman European Respiratory Journal 44 (Suppl 58), 2014 | 3 | 2014 |
| Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study JR Hurst, K Kostikas, KR Chapman, SM Frent, M Larbig, R Fogel, ... European Respiratory Journal 52 (suppl 62), 2018 | 2 | 2018 |
